Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.67 |
| ▸ | NPC1 | O15118 | 3/20 | 0.67 |
| ▸ | PKM | P14618 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | AHR | P35869 | 1/20 | 0.55 |
| ▸ | NAMPT | P43490 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30504811 | 0.85 | RAB9A (0.89) | RAB9ANPC1PKMKDM4ELMNA | |
| SCHEMBL2414088 | 0.84 | NPC1 (0.59) | RAB9ANPC1PKMKDM4ELMNA | |
| SCHEMBL30352289 | 0.82 | KDM4E (0.62) | RAB9ANPC1PKMKDM4ELMNA | |
| SCHEMBL9262080 | 0.82 | RAB9A (0.71) | RAB9ANPC1PKMKDM4ELMNA | |
| SCHEMBL1070561 | 0.82 | KDM4E (0.62) | RAB9ANPC1PKMKDM4ELMNA | |
| SCHEMBL15131707 | 0.82 | RAB9A (0.66) | RAB9ANPC1PKMKDM4ELMNA | |
| SCHEMBL6877095 | 0.82 | RAB9A (0.65) | RAB9ANPC1PKMKDM4ELMNA | |
| SCHEMBL6630167 | 0.80 | RAB9A (0.79) | RAB9ANPC1PKMKDM4ELMNA | |
| SCHEMBL12828408 | 0.79 | RAB9A (0.67) | RAB9ANPC1PKMKDM4ELMNA | |
| SCHEMBL6989004 | 0.79 | RAB9A (0.71) | RAB9ANPC1PKMKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3939973-A1 | HETERO-HALO INHIBITORS OF HISTONE DEACETYLASE | Alkermes, Inc. (US) | 2022-01-19 | — | — | EP | disclosed |
| EP-1577301-B1 | Antithrombotic diaminocyclohexane derivatives | DAIICHI SANKYO CO LTD (JP) | 2012-09-12 | — | — | EP | disclosed |
| US-20110312990-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-22 | — | — | US | disclosed |
| EP-2343290-A1 | Diamine derivatives as factor X inhibitors | Daiichi Sankyo Company, Limited (JP) | 2011-07-13 | — | — | EP | disclosed |
| US-20110077266-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-31 | — | — | US | disclosed |
| CN-1751025-B | Diamine derivatives | DAIICHI SEIYAKU CO | 2010-05-12 | — | — | CN | disclosed |
| US-20100099660-A1 | METHOD FOR TREATING THROMBOSIS OR EMBOLISM AND RELATED DISEASES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
| US-20100093785-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20090270446-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| US-7576135-B2 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-08-18 | — | — | US | disclosed |
| US-20050245565-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| EP-1577301-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
| US-20050119486-A1 | Diamine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2005-06-02 | — | — | US | disclosed |
| US-20050020645-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1415992-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | disclosed |
| EP-1405852-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | disclosed |
| US-5416218-A | Photographic silver halide material | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1995-05-16 | — | — | US | disclosed |
| EP-0444506-B1 | Silver halide photographic materials containing arylhydrazides | DU PONT DEUTSCHLAND (DE) | 1994-10-26 | — | — | EP | disclosed |
| US-5190847-A | Ultrahigh Contrast | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-03-02 | — | — | US | disclosed |
| EP-0444506-A1 | Silver halide photographic materials containing arylhydrazides | DU PONT DE NEMOURS (DEUTSCHLAND) GMBH (DE) | 1991-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270446-A1 | DIAMINE DERIVATIVES | F2, TFPI, F3 | RAB9A 2734/4885NPC1 4535/4885PKM 2825/4885 |
| US-20100099660-A1 | METHOD FOR TREATING THROMBOSIS OR EMBOLISM AND RELATED DISEASES | F2, PLAT, MPL | RAB9A 1817/4885NPC1 3353/4885PKM 1611/4885 |
| US-20050020645-A1 | Diamine derivatives | C9, C1S, C1R | RAB9A 3294/4885NPC1 3358/4885PKM 4558/4885 |
| US-20050245565-A1 | Diamine derivatives | C9, C1S, C1R | RAB9A 3294/4885NPC1 3358/4885PKM 4558/4885 |
| US-20100093785-A1 | DIAMINE DERIVATIVES | C9, C1S, C1R | RAB9A 3393/4885NPC1 3819/4885PKM 4487/4885 |
| US-20050119486-A1 | Diamine derivatives | C9, C1S, C1R | RAB9A 3294/4885NPC1 3358/4885PKM 4558/4885 |
| US-20110077266-A1 | Diamine Derivatives | F2, TFPI, F3 | RAB9A 2734/4885NPC1 4535/4885PKM 2825/4885 |
| US-20110312990-A1 | Diamine Derivatives | C9, C1S, C1R | RAB9A 3496/4885NPC1 3454/4885PKM 4584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.